(CercleFinance.com) – The German scientific company Proteros announced on Monday that it would deepen its collaboration in the field of oncology with the biopharmaceutical giant AstraZeneca.
This new step, which follows on from an existing partnership concluded last year, concerns the development of small molecule inhibitors targeting a second epigenetic protein associated with cancer.
While genetics focuses on the study of genes, epigenetics is interested in a ‘layer’ of complementary information that defines how these genes will be used or not by cells.
The new agreement provides for the payment to Proteros of funds for research activities, to which could be added milestone payments of 75 million euros, not including royalties on future drug sales.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
